.: Followup to REPCF cure for baldness. Interview with CEO :.
NBT Two-Minute Drill Interview with David Hall, CEO of Replicel Life Sciences
We recently interviewed David Hall, CEO of Replicel Life Sciences, Inc., on the upcoming Phase I/IIa clinical trial results “reveal” for their cell-based hair regeneration technology some 90 or so days away.
With positive results expected from their current Phase I/IIa trial, Replicel will move immediately into a 100-patient dosing trial from which it hopes to build an overwhelming set of successful data for the patented RepliCel™ procedure for minimally invasive hair cell growth and implantation.
With two successful data-sets in hand, Replicel intends to sell its entire hair growth and implantation business to the highest Big Pharma/Big Bio bidder. NBT analyses the value of their follicular regeneration business at about $500 million—or more than $10 a share with an expected 10 million share dilution from money raising activities in 2012.
Plus, you state: "With positive results expected from their current Phase I/IIa trial..." This is very a speculative play -- early stage of development -- for a treatment that borrows from -- and reminds folks of -- Fibrocell's "Laviv" -- the only autologous cell treatment in the known universe.
Me think AGN's baldness treatment -- for it's proven efficacy -- is perhaps further down the road on the clinical track.